Log in to save to my catalogue

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase...

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2926519398

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance to immune checkpoint blockade is common. Understa...

Alternative Titles

Full title

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2926519398

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2926519398

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/s41591-024-02808-y

How to access this item